Key clinical point: Inebilizumab reduces the risk of NMOSD attacks.
Major finding: Compared with placebo, inebilizumab reduces the risk of an attack by 73%.
Study details: A randomized, controlled study of 231 patients with NMOSD.
Disclosures: This study was funded by Viela Bio and MedImmune.
Cree B et al. AAN 2019. Abstract Plen02.001.